Patents Assigned to Hvidovre Hospital
  • TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER
    Publication number: 20080261246
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
    Type: Application
    Filed: April 11, 2008
    Publication date: October 23, 2008
    Applicants: RIGSHOSPITALET, HVIDOVRE HOSPITAL
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brunner, Hans Jorgen Nielsen
  • Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
    Patent number: 7374886
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 20, 2008
    Assignees: Rigshospitalet, Hvidovre Hospital
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brünner, Hans Jørgen Nielsen
  • Method for detecting, screening and/or montoring a cancer in individual
    Publication number: 20060154245
    Abstract: The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual.
    Type: Application
    Filed: March 28, 2005
    Publication date: July 13, 2006
    Applicants: Rigshospitalet, Hvidovre Hospital
    Inventors: Lasse Hessel, Jesper Malling, Nils Brunner, Mads Holten-Andersen, Hans Nielsen
  • Method for detecting, screening and/or monitoring a cancer in an individual
    Publication number: 20060014224
    Abstract: The invention relates to a method for screening and/or detecting and/or monitoring a cancer in an individual, said method comprising determining a first parameter represented by the concentration of TIMP-1 in at least one excreta, e.g. saliva, from the individual. The invention provides a method that without the need to use a blood sample is suitable for facilitating the early diagnosis of a cancer, monitoring the recurrence of a cancer, and/or monitoring the status of a cancer or the effect of cancer treatment in an individual.
    Type: Application
    Filed: September 26, 2003
    Publication date: January 19, 2006
    Applicant: Hvidovre Hospital
    Inventors: Nils Brunner, Lasse Hessel, Jesper Malling, Mads Holten-Andersen, Hans Nielsen